Skip links



For Post Ocular Surgery Freya has developed and demonstrated MoxiLensTM - antibiotic eluting contact lenses provide sustained release resulting in therapeutic concentrations for extended durations, eliminating the peaks and troughs in concentrations from drops, which may cause sub-therapeutic concentration between drop instillations, which can lead to infection proliferation and/or development of resistance

0  Milion +
0  Milion +

Bacterial Conjunctivitis Infections per Year

Lead Market

Introducing the First Antibiotic Bandage Contact Lens - MoxiLensTM


MoxiLens™ releases drug for 72 hours - vs just 2 hours for a conventional lens

Lab Tests indicate a 72-hour antibiotic treatment for the MoxiLensTM vs. non-vitamin E control lens

Mass Release (µg)

Lab Tests indicate a 72-hour antibiotic treatment for the MoxiLensTM vs. non-vitamin E control lens

Physician Usage

Feedback on MoxiLensTM has been very positive

Post Surgical

“good results”

Corneal Erosion

“Worked well”. “It is a game changer”.

“MoxiLensTM lens was used successfully over 3 days to treat a recurrent corneal erosion after surgical complications. The lens was comfortable and healed the epithelial defect.”

Post PRK

“Healed without issues. Used for 4 days. Comfortable. Also, prescribed FML drops.”

Corneal Erosion

”Used MoxiLensTM in patients with pathology (ABMD, RCE, etc) & refractive error. Both patients found lens comfortable & reduced the number of drops & cost was noted. Rehab times were quick with rapid recovery in all patients”

Corneal Abrasion

“I often use a bandage CL to provide comfort & protection for treating large corneal abrasions. The MoxiLensTM added another layer of confidence that the cornea would heal with minimal risk of infection.”

“Used to treat an abrasion for 48 hours and then used drops to finish the job.” “Used on an older patient who had a corneal abrasion & noncompliant with drops. The abrasion healed without incident or discomfort.”


“The MoxiLensTM provided excellent coverage & comfort, promoting healing while delivering therapeutic levels on an antibiotic.” “ The MoxiLensTM is very beneficial addition to my toolbox for treating corneal disease. And provides 24-hour antibiotic delivery to the cornea – improves compliance.”

Corneal Ulcer

“The patient was not a previous CL wearer. The patient had no discomfort whatsoever. The patient was seen daily for the first 2-3 days, then again 3 days later. The CL stayed in the eye for 7 days with no additional topical meds for one week. No problems. I would definitely store MoxiLensTM on the shelf in case of an emergency.”

FDA Approval Target Product Profile

Vitamin E modified bandage contact lens loaded with Moxifloxacin hydrochloride ophthalmic solution for treatment of bacterial conjunctivitis (MoxiLensTM)


A senofilcon A contact bandage lens






vitamin E





1 MoxiLensTM worn in infected eye continuously up to 72 hours


Single use vials with > 1 year shelf life

Target Duration

72 hours


Reimbursement when FDA approved

Target Endpoints

MoxiLensTM is a disposable senofilcon A bandage drug-eluting contact lens packaged with a topical fluoroquinolone anti-infective indicated for the treatment of bacterial conjunctivitis These lenses have been approved for daily and extended wear for up to 3 or 6 nights/4 or 7 days of continuous wear. Pediatrics (12 years of age and older): The safety and efficacy of the MoxiLensTM has been established.

Clinical Plan

Clinical Development Plan Rapidly Progressing Toward 2026 MoxiLens™ NDA Filing

2H 2022

  • SBIR Grant Received
  • IND Accepted
  • Safety Study Completed

3Q 2023

  • FDA Type C Meeting held September 6 providing program agreement per IND update
  • Select & Prepare CRO
  • Phase 2 Clinical Begins


  • Phase 2 Clinical Complete
  • Phase 2 Data Review
  • Select & Prepare CMO

1H 2025

  • Initiate Phase 3 Trial